Clinical trial
Prediction of Drug Interactions With CYP2C9 Substrates
NCT00226538 · Hadassah Medical Organization, Other · Completed
Key facts
| NCT number | NCT00226538 |
|---|---|
| Title | Prediction of Drug Interactions With CYP2C9 Substrates |
| Official title | Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo. |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Healthy Volunteers |
| Intervention type | Drug |
| Interventions | Phenytoin, Rifampicin, Diclophenac, Fluconazole |
| Enrollment | 16 |
| Start date | Aug 1, 1999 |
| First posted | Sep 27, 2005 |
| Last update posted | Oct 29, 2008 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: